Tests how naltrexone affects ketamine's impact on blood flow in major depression, suggesting important connections to symptoms.
Accumulating evidence suggests that the opioid system may modulate ketamine’s rapid antidepressant effects. The objective of this study was to test whether opioid system modulation via naltrexone alters ketamine’s acute effects on regional cerebral blood flow (rCBF) in major depressive disorder (MDD), and whether these changes relate to symptom measures and map onto receptor density profiles.
No takes yet. Share an insight, caveat, or question.
Jelen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: